189 related articles for article (PubMed ID: 36085339)
1. Levoketoconazole in the treatment of patients with endogenous Cushing's syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS).
Pivonello R; Zacharieva S; Elenkova A; Tóth M; Shimon I; Stigliano A; Badiu C; Brue T; Georgescu CE; Tsagarakis S; Cohen F; Fleseriu M
Pituitary; 2022 Dec; 25(6):911-926. PubMed ID: 36085339
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial.
Fleseriu M; Pivonello R; Elenkova A; Salvatori R; Auchus RJ; Feelders RA; Geer EB; Greenman Y; Witek P; Cohen F; Biller BMK
Lancet Diabetes Endocrinol; 2019 Nov; 7(11):855-865. PubMed ID: 31542384
[TBL] [Abstract][Full Text] [Related]
3. Levoketoconazole in the Treatment of Patients With Cushing's Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study.
Pivonello R; Elenkova A; Fleseriu M; Feelders RA; Witek P; Greenman Y; Geer EB; Perotti P; Saiegh L; Cohen F; Arnaldi G
Front Endocrinol (Lausanne); 2021; 12():595894. PubMed ID: 33897615
[TBL] [Abstract][Full Text] [Related]
4. Levoketoconazole treatment in endogenous Cushing's syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes.
Fleseriu M; Auchus RJ; Greenman Y; Zacharieva S; Geer EB; Salvatori R; Pivonello R; Feldt-Rasmussen U; Kennedy L; Buchfelder M; Biller BM; Cohen F; Heaney AP
Eur J Endocrinol; 2022 Dec; 187(6):859-871. PubMed ID: 36251618
[TBL] [Abstract][Full Text] [Related]
5. Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing's syndrome.
Geer EB; Salvatori R; Elenkova A; Fleseriu M; Pivonello R; Witek P; Feelders RA; Bex M; Borresen SW; Puglisi S; Biller BMK; Cohen F; Pecori Giraldi F
Pituitary; 2021 Feb; 24(1):104-115. PubMed ID: 33216275
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
[TBL] [Abstract][Full Text] [Related]
7. Levoketoconazole: a novel treatment for endogenous Cushing's syndrome.
Fleseriu M; Auchus RJ; Pivonello R; Salvatori R; Zacharieva S; Biller BMK
Expert Rev Endocrinol Metab; 2021 Jul; 16(4):159-174. PubMed ID: 34380370
[No Abstract] [Full Text] [Related]
8. A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease.
Tanaka T; Satoh F; Ujihara M; Midorikawa S; Kaneko T; Takeda T; Suzuki A; Sato M; Shimatsu A
Endocr J; 2020 Aug; 67(8):841-852. PubMed ID: 32378529
[TBL] [Abstract][Full Text] [Related]
9. Levoketoconazole, the 2S,4R Enantiomer of Ketoconazole, a New Steroidogenesis Inhibitor for Cushing's Syndrome Treatment.
Creemers SG; Feelders RA; de Jong FH; Franssen GJH; de Rijke YB; van Koetsveld PM; Hofland LJ
J Clin Endocrinol Metab; 2021 Mar; 106(4):e1618-e1630. PubMed ID: 33399817
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial.
Lacroix A; Gu F; Gallardo W; Pivonello R; Yu Y; Witek P; Boscaro M; Salvatori R; Yamada M; Tauchmanova L; Roughton M; Ravichandran S; Petersenn S; Biller BMK; Newell-Price J;
Lancet Diabetes Endocrinol; 2018 Jan; 6(1):17-26. PubMed ID: 29032078
[TBL] [Abstract][Full Text] [Related]
11. Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies.
Fleseriu M; Castinetti F
Pituitary; 2016 Dec; 19(6):643-653. PubMed ID: 27600150
[TBL] [Abstract][Full Text] [Related]
12. Randomized Trial of Osilodrostat for the Treatment of Cushing Disease.
Gadelha M; Bex M; Feelders RA; Heaney AP; Auchus RJ; Gilis-Januszewska A; Witek P; Belaya Z; Yu Y; Liao Z; Ku CHC; Carvalho D; Roughton M; Wojna J; Pedroncelli AM; Snyder PJ
J Clin Endocrinol Metab; 2022 Jun; 107(7):e2882-e2895. PubMed ID: 35325149
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of ketoconazole as a treatment for Cushing's disease in a retrospective cohort.
Viecceli C; Mattos ACV; Costa MCB; de Melo RB; Rodrigues TDC; Czepielewski MA
Front Endocrinol (Lausanne); 2022; 13():1017331. PubMed ID: 36277689
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a Phase II study with an optional extension phase (LINC 2).
Fleseriu M; Biller BMK; Bertherat J; Young J; Hatipoglu B; Arnaldi G; O'Connell P; Izquierdo M; Pedroncelli AM; Pivonello R
Pituitary; 2022 Dec; 25(6):959-970. PubMed ID: 36219274
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study.
Fleseriu M; Petersenn S; Biller BMK; Kadioglu P; De Block C; T'Sjoen G; Vantyghem MC; Tauchmanova L; Wojna J; Roughton M; Lacroix A; Newell-Price J
Clin Endocrinol (Oxf); 2019 Dec; 91(6):776-785. PubMed ID: 31465533
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and safety of osilodrostat in patients with Cushing's disease: results from the LINC 4 study extension.
Gadelha M; Snyder PJ; Witek P; Bex M; Belaya Z; Turcu AF; Feelders RA; Heaney AP; Paul M; Pedroncelli AM; Auchus RJ
Front Endocrinol (Lausanne); 2023; 14():1236465. PubMed ID: 37680892
[TBL] [Abstract][Full Text] [Related]
17. Cushing's disease: adrenal steroidogenesis inhibitors.
Pivonello R; Simeoli C; Di Paola N; Colao A
Pituitary; 2022 Oct; 25(5):726-732. PubMed ID: 36036308
[TBL] [Abstract][Full Text] [Related]
18. Hyperthyroidism due to thyroid-stimulating hormone secretion after surgery for Cushing's syndrome: a novel cause of the syndrome of inappropriate secretion of thyroid-stimulating hormone.
Tamada D; Onodera T; Kitamura T; Yamamoto Y; Hayashi Y; Murata Y; Otsuki M; Shimomura I
J Clin Endocrinol Metab; 2013 Jul; 98(7):2656-62. PubMed ID: 23671315
[TBL] [Abstract][Full Text] [Related]
19. Approach to the Patient Treated with Steroidogenesis Inhibitors.
Castinetti F; Nieman LK; Reincke M; Newell-Price J
J Clin Endocrinol Metab; 2021 Jun; 106(7):2114-2123. PubMed ID: 33675650
[TBL] [Abstract][Full Text] [Related]
20. High variability in baseline urinary free cortisol values in patients with Cushing's disease.
Petersenn S; Newell-Price J; Findling JW; Gu F; Maldonado M; Sen K; Salgado LR; Colao A; Biller BM;
Clin Endocrinol (Oxf); 2014 Feb; 80(2):261-9. PubMed ID: 23746264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]